Dr. Mark Puder, MD, PhD
Claim this profileBoston Children's Hospital
Studies Malabsorption Syndrome
Studies Postprandial Fullness Syndrome
2 reported clinical trials
2 drugs studied
Affiliated Hospitals
Clinical Trials Mark Puder, MD, PhD is currently running
RELiZORB
for Malabsorption Syndrome
Children with inadequate intestinal absorption due to loss of large amounts of small bowel require intravenous nutrition (feeding through the vein) to sustain hydration and nutrition to avoid starvation and dehydration; however, intravenous (IV) nutrition can lead to complications including liver failure. Tube feeding directly to the small intestine avoids the complications of IV nutrition, but fats are not fully digestible due to inadequate bowel function. We propose to predigest the fat using a small cartridge attached to the feeding tube to allow for rapid absorption with the possibility of reducing or eliminating the need for intravenous nutrition
Recruiting1 award N/A10 criteria
NST-6179
for Liver Disease
This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-associated liver disease (IFALD) receiving parenteral nutrition (PN). The study will be conducted in 2 sequential parts. Up to 36 subjects diagnosed with IFALD will be enrolled in the study, of which up to 18 subjects will be enrolled in each of the 2 parts and randomized (2:1) to receive NST-6179 (N=12/part) or matched placebo (N=6/part). Subjects in Part A will receive once daily (QD) oral administration of 800 mg (32 mL solution) NST-6179 or placebo for 4 weeks. The NST-6179 dose for Part B is planned to be 1200 mg QD for 12 weeks. Actual dose, however, will be determined during the safety review meeting.
Recruiting0 awards Phase 210 criteria
More about Mark Puder, MD, PhD
Clinical Trial Related6 years of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Mark Puder, MD, PhD has experience with
- RELiZORB
- NST-6179
Breakdown of trials Mark Puder, MD, PhD has run
Malabsorption Syndrome
Postprandial Fullness Syndrome
Leaky Gut Syndrome
Short Bowel Syndrome
Malabsorption
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Puder, MD, PhD specialize in?
Mark Puder, MD, PhD focuses on Malabsorption Syndrome and Postprandial Fullness Syndrome. In particular, much of their work with Malabsorption Syndrome has involved treating patients, or patients who are undergoing treatment.
Is Mark Puder, MD, PhD currently recruiting for clinical trials?
Yes, Mark Puder, MD, PhD is currently recruiting for 2 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Mark Puder, MD, PhD has studied deeply?
Yes, Mark Puder, MD, PhD has studied treatments such as RELiZORB, NST-6179.
What is the best way to schedule an appointment with Mark Puder, MD, PhD?
Apply for one of the trials that Mark Puder, MD, PhD is conducting.
What is the office address of Mark Puder, MD, PhD?
The office of Mark Puder, MD, PhD is located at: Boston Children's Hospital, Boston, Massachusetts 02115 United States. This is the address for their practice at the Boston Children's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.